The effect of fat intake and antihypertensive drug therapy on serum lipid profile: a cross-sectional survey of serum lipids in male and female hypertensives

2010 ◽  
Vol 343 (1-2) ◽  
pp. 37-47 ◽  
Author(s):  
Rakesh Sharma ◽  
T. C. Raghuram ◽  
U. Brahmoji Rao ◽  
Robert J. Moffatt ◽  
Kamla Krishnaswamy
Keyword(s):  
Drug Therapy ◽  
Lipid Profile ◽  
Antihypertensive Drug ◽  
Serum Lipid ◽  
Serum Lipids ◽  
Antihypertensive Drug Therapy ◽  
Fat Intake ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Male And Female

Serum Lipid Profile in Diffuse versus Limited Systemic Sclerosis Data from the SASS cohort

2018 ◽  
Vol 69 (2) ◽  
pp. 403-406
Author(s):  
Codrina Ancuta ◽  
Cristina Pomirleanu ◽  
Cristina Iordache ◽  
Magda Ecaterina Antohe ◽  
Rodica Chirieac ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Serum Lipid ◽  
Total Cholesterol Level ◽  
Cross Sectional Study ◽  
Serum Lipid Profile ◽  
Serum Triglycerides ◽  
Cross Sectional ◽  
Topoisomerase 1

Data about lipoprotein changes and their link with cardiovascular disease and atherosclerosis in systemic sclerosis (SSc) are still challenging. We aimed to evaluate serum lipid profile of patients with SSc and to identify potential relation with different disease specific characteristics (clinical, serological, inflammatory tests) in a cross-sectional study. Standard assessments comprised SSc-related parameters (disease subtype, clinical spectrum, immunological tests) and lipid metabolism (total cholesterol and fractions, triglycerides). Impaired lipid profile (low serum HDL- and high LDL-cholesterol, increased serum triglycerides, slightly modification in total cholesterol level) significantly correlated with diffuse SSc, activity (EUSTAR) and severity (MEDSGER), as well as seropositivity for specific antibodies (anti-centromere and anti-topoisomerase 1). The dyslipidemic profile might represent a pathobiological pathway for atherosclerosis in SSc.

Sign in / Sign up

Export Citation Format

Share Document